Crossing the Atlantic: why European biotechs struggle to win US media trust

Differences in regulatory culture, timing and media expectations often shape how credibility is assessed on either side of the Atlantic

By Shirley Johnson

European biotech companies with strong science and growing international ambitions are increasingly seeking to establish a presence in the US. Media visibility is often seen as one way to support that ambition. Yet despite credible progress, many find that their stories generate limited traction in US biotech media – or worse, attract a level of scrutiny that feels misaligned with their stage of development.

This disconnect is often assumed to be a question of access or storytelling. In practice, it more frequently reflects a misalignment between European communication norms and how US biotech media evaluates credibility. Differences in regulatory signalling, tolerance for risk and expectations around timing can all influence whether progress is perceived as meaningful, premature or insufficiently consequential.

Understanding this divergence has become more important as development timelines compress, regulatory pathways accelerate and scrutiny intensifies across global markets. For European biotechs navigating US attention, the challenge is not simply gaining coverage, but ensuring that visibility, when it occurs, reinforces credibility rather than testing it.

In the US biotech media environment, stories that endure are typically those that explain why something matters now. Journalists tend to focus on developments that alter expectations or elevate scrutiny, rather than those that confirm steady progress.  When that distinction is unclear, even strong science can struggle to register as news.

This dynamic is often most visible in disease areas where incremental progress carries genuine clinical importance. For example, a European biotech developing a new breast cancer therapy designed to reduce treatment-related side effects may reasonably view early regulatory engagement or preliminary safety signals as significant milestones. Within a European context, such progress can signal responsible development and scientific validation.

In the US biotech media environment, however, attention is more likely to follow moments that materially change how that therapy will be evaluated – such as comparative clinical data, a regulatory designation, or evidence that the approach could alter standards of care. Absent a clear inflection point, improvements that meaningfully benefit patients may still struggle to register as newsworthy, not because they lack value, but because they do not yet alter expectations around risk, adoption or regulatory trajectory.

Where European biotech companies have successfully gained US media traction, it is typically at moments when regulatory, clinical and commercial context converge. These tend to be later-stage organisations approaching pivotal trial data, regulatory decisions or significant strategic transactions, where visibility coincides with heightened external scrutiny rather than preceding it.

Regulatory culture shapes not only how medicines are developed, but also how progress is communicated – and how that progress is interpreted by the media. In Europe and the US, differences in regulatory structure and signalling help explain why similar developments can be read very differently on either side of the Atlantic.

In the European context, regulatory progress is often conveyed through process-oriented milestones. Engagement with the European Medicines Agency and national authorities, scientific advice, protocol alignment and ongoing assessment can represent meaningful validation that development is proceeding appropriately. These steps carry real significance for companies, regulators and patients, even when no single milestone dramatically alters a programme’s overall trajectory.

US regulatory signalling tends to be more decision-led and threshold-based. Milestones associated with the US Food and Drug Administration – such as clinical clearances, regulatory designations, submissions or approvals – create clearer inflection points. These moments draw sharper distinctions between pre- and post-status, making them easier for journalists to frame as consequential changes in risk, timing or market relevance.

As a result, US biotech media expectations are often calibrated to moments that visibly reshape how a product or company will be judged. European regulatory progress, while scientifically rigorous, may signal continuity rather than change, and therefore register as less newsworthy in a US media environment that prioritises inflection over process.

These structural differences do not reflect variations in scientific standards, but in how regulatory systems communicate momentum. For companies operating across both markets, this divergence can influence whether progress is perceived as validation, acceleration or simply steady advancement – and, ultimately, whether it attracts sustained media attention.

Beyond regulatory and clinical inflection points, US biotech media interest often builds where external validation accumulates, particularly when it originates from institutions or forums familiar to US audiences.

One such signal is peer-reviewed publication. When data appears in well-regarded scientific journals, it can recalibrate how a programme is perceived by journalists, not because publication guarantees success, but because it introduces independent scientific scrutiny that is widely recognised across markets.

Similarly, collaboration with US-based partners – including pharmaceutical companies, academic institutions or research networks – can influence media attention by situating a European company within a US-relevant ecosystem. These relationships often help contextualise a programme competitively and geographically, making it easier for journalists to assess relevance and comparability.

Engagement with patient or professional organisations can also shape coverage indirectly, particularly when it signals unmet need, advocacy momentum or broader clinical interest. In the US media environment, such alignment can add dimension to a story without functioning as a substitute for data or regulatory progress.

Finally, visibility at major medical meetings often plays a role. Presentations at established scientific congresses provide moments of collective attention, where journalists are already primed to evaluate new information. In these settings, interest is typically driven less by presence alone than by how presented data alters expectations or highlights emerging differentiation.

Taken together, these factors do not independently create newsworthiness. Rather, they tend to reinforce perceptions of readiness and relevance, particularly when they coincide with regulatory, clinical or commercial inflection points.

When visibility and scrutiny remain in proportion, it is often because expectations have been carefully managed long before wider attention arrives. In practice, this balance is less the result of individual announcements than of how a company’s development story has been contextualised over time.

In cases where scrutiny feels measured rather than abrupt, companies tend to enter the public conversation with a clear sense of how their progress will be evaluated externally. Media narratives are shaped around regulatory stage, evidentiary maturity and competitive context, reducing the risk that attention outpaces substance. From a journalistic perspective, this clarity allows coverage to develop incrementally, rather than compressing evaluation into a single moment.

Balance is also supported when visibility aligns with moments that naturally invite interrogation. When attention coincides with data releases, regulatory movement or strategic transactions, scrutiny is expected and easier to absorb. Questions feel proportionate because they arise at points where uncertainty has narrowed, rather than widened.

Conversely, when visibility is pursued without sufficient contextual grounding, scrutiny can feel premature. In such instances, media interest may surface questions earlier than anticipated, not as a critique of the science itself, but as a response to perceived acceleration. The resulting tension can make otherwise credible progress appear fragile.

Viewed through this lens, successful navigation of US media attention is less about maximising exposure than about sequencing it. When visibility follows readiness, scrutiny tends to reinforce credibility. When it precedes it, scrutiny often becomes the story.

For European biotechs operating across markets, credibility is not built in a single announcement or article, but accumulated over time through consistency, restraint and context. US media trust often develops gradually, shaped as much by what companies choose not to overstate as by what they disclose. In an environment where timelines are compressed and expectations evolve quickly, measured communication can function as a strategic asset rather than a limitation.

The challenge, then, is not translating European progress into US headlines, but recognising how different systems signal momentum and significance. As regulatory, clinical and commercial landscapes continue to converge globally, alignment, rather than acceleration, becomes the more durable foundation for visibility.

In that context, media attention is most effective when it reflects preparedness rather than aspiration, and credibility is strengthened not by how early a story appears, but by how well it endures.

Shirley Johnson is an adjunct professor at the University of Delaware in the US